Abstract: Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
Abstract: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed. In some embodiments, the active agent is fenofibrate. In other embodiments, the fenofibrate compositions are in a treatment form that that is bioequivalent to TriCorĀ® 145 mg or 48 mg.
Type:
Application
Filed:
June 26, 2007
Publication date:
February 28, 2008
Applicant:
MUTUAL PHARMACEUTICAL COMPANY, INC.
Inventors:
Kristin Arnold, Hengsheng Feng, Kurt Nielsen
Abstract: Disclosed herein is a method of using quinine. The method comprises informing a user that quinine does not induce the activity of a cytochrome p450 isozyme.
Type:
Application
Filed:
January 5, 2007
Publication date:
February 21, 2008
Applicant:
MUTUAL PHARMACEUTICAL COMPANY, INC.
Inventors:
Richard Howard Roberts, Jie Du, Matthew William Davis, Kurt R. Nielsen
Abstract: A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the Cmax for carisoprodol compared to administration in the absence of food. In one embodiment, informing comprises providing printed labeling instructions. Also included are articles comprising a carisoprodol formulation and prescribing information, and methods of manufacturing carisoprodol dosage forms. Included are measures intended to increase the safe use of narrow therapeutic medications with carisoprodol.
Abstract: Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.